HUP9901469A3 - Stable reagents for the preparation of radiopharmaceuticals - Google Patents

Stable reagents for the preparation of radiopharmaceuticals

Info

Publication number
HUP9901469A3
HUP9901469A3 HU9901469A HUP9901469A HUP9901469A3 HU P9901469 A3 HUP9901469 A3 HU P9901469A3 HU 9901469 A HU9901469 A HU 9901469A HU P9901469 A HUP9901469 A HU P9901469A HU P9901469 A3 HUP9901469 A3 HU P9901469A3
Authority
HU
Hungary
Prior art keywords
radiopharmaceuticals
preparation
stable reagents
reagents
stable
Prior art date
Application number
HU9901469A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of HUP9901469A2 publication Critical patent/HUP9901469A2/hu
Publication of HUP9901469A3 publication Critical patent/HUP9901469A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
HU9901469A 1995-06-07 1996-06-07 Stable reagents for the preparation of radiopharmaceuticals HUP9901469A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/476,296 US5750088A (en) 1993-03-30 1995-06-07 Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals

Publications (2)

Publication Number Publication Date
HUP9901469A2 HUP9901469A2 (hu) 1999-08-30
HUP9901469A3 true HUP9901469A3 (en) 2000-02-28

Family

ID=23891282

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901469A HUP9901469A3 (en) 1995-06-07 1996-06-07 Stable reagents for the preparation of radiopharmaceuticals

Country Status (29)

Country Link
US (2) US5750088A (hu)
EP (1) EP0832068B1 (hu)
JP (1) JPH11507364A (hu)
KR (1) KR19990022573A (hu)
CN (1) CN1192733A (hu)
AR (1) AR003959A1 (hu)
AT (1) ATE233241T1 (hu)
AU (1) AU718683B2 (hu)
BR (1) BR9609003A (hu)
CA (1) CA2222183A1 (hu)
CZ (1) CZ380197A3 (hu)
DE (1) DE69626392T2 (hu)
EA (1) EA000742B1 (hu)
EE (1) EE9700313A (hu)
ES (1) ES2193245T3 (hu)
HR (1) HRP960250A2 (hu)
HU (1) HUP9901469A3 (hu)
IL (1) IL118468A0 (hu)
LT (1) LT4380B (hu)
LV (1) LV12044B (hu)
MX (1) MX9709126A (hu)
MY (1) MY133974A (hu)
NO (1) NO975678L (hu)
NZ (1) NZ310799A (hu)
PL (1) PL323995A1 (hu)
SI (1) SI9620076B (hu)
SK (1) SK163497A3 (hu)
WO (1) WO1996040637A1 (hu)
ZA (1) ZA964854B (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033627A2 (en) * 1996-03-13 1997-09-18 Du Pont Pharmaceuticals Company New ternary radiopharmaceutical complexes
US6416733B1 (en) * 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
AU736481C (en) * 1996-10-07 2002-06-06 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
US6403054B1 (en) 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
WO1999051628A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
HRP990317A2 (en) * 1998-10-13 2000-06-30 Du Pont Pharm Co A process for the preparation of a thrombus imaging agent
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
AU2371400A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
CN1356913A (zh) 1998-12-18 2002-07-03 杜邦药品公司 玻连蛋白受体拮抗剂药物
IL145130A0 (en) * 1999-03-26 2002-06-30 Du Pont Pharm Co Method for localization of blood clots
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
US6534038B2 (en) * 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
WO2002036173A2 (en) * 2000-11-03 2002-05-10 Bristol-Myers Squibb Pharma Company Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
HUP0401904A3 (en) * 2001-08-08 2009-01-28 Bristol Myers Squibb Pharma Co Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
CA2526556C (en) * 2003-07-24 2012-09-25 Bracco Imaging S.P.A. Stable radiopharmaceutical compositions and methods for their preparation
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
CN101252954A (zh) * 2005-06-30 2008-08-27 布里斯托尔-迈尔斯斯奎布药品公司 作为显像剂的酰肼偶联物
JPWO2007046411A1 (ja) * 2005-10-19 2009-04-23 大日本住友製薬株式会社 イソキサゾール化合物の安定化方法
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
KR20080080206A (ko) * 2005-12-20 2008-09-02 아스트라제네카 아베 Ｇａｂａａ-수용체 조절제로서의 치환된 신놀린 유도체 및그의 합성 방법
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
TW200911760A (en) * 2007-06-19 2009-03-16 Astrazeneca Ab Compounds and uses thereof
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
SI2382215T1 (sl) * 2008-12-29 2020-06-30 Sanofi Derivati 2-piridin-2-il-pirazol-3(2H)-ona, njihova priprava in njihova terapevtska uporaba
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
CA2748411A1 (fr) 2008-12-29 2010-07-08 Sanofi Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CN110818624B (zh) * 2019-11-22 2022-11-22 华东理工大学 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
CA1300608C (en) * 1985-05-10 1992-05-12 Edward A. Deutsch 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo
GB8624272D0 (en) * 1986-10-09 1986-11-12 Amersham Int Plc Cationic complexes of tc-99m
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
WO1989005150A1 (en) 1987-12-10 1989-06-15 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
EP0403524B1 (fr) * 1988-03-09 1993-02-10 Cis Bio International Preparation de complexes nitruro utilisables comme produits radiopharmaceutiques
GB8808414D0 (en) * 1988-04-11 1988-05-11 Amersham Int Plc Ligands & cationic complexes thereof with technetium-99m
AU3569189A (en) 1988-04-29 1989-11-24 New England Deaconess Hospital Corporation Hybrid peptides and methods of their use
US5002754A (en) * 1988-06-15 1991-03-26 University Of Cincinnati Technetium (III/II) imaging agents
WO1990003391A1 (en) 1988-09-29 1990-04-05 Biogen, Inc. Hirudin peptides
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
GB8902362D0 (en) * 1989-02-03 1989-03-22 Amersham Int Plc Cationic complexes of technetium-99m
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
US4917879A (en) * 1989-05-19 1990-04-17 University Of Cincinnati 99MTC(III) myocardial imaging agents that are effective in humans
US4957728A (en) * 1989-05-19 1990-09-18 University Of Cincinnati Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans
GB8914020D0 (en) 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
EP0410537A1 (en) 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
GB8919488D0 (en) * 1989-08-29 1989-10-11 Amersham Int Plc New cores for technetium radiopharmaceuticals
ZA907743B (en) 1989-10-03 1991-07-31 Merrell Dow Pharma Radiolabeled anticoagulant peptides
US5086069A (en) 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
FR2664166A1 (fr) * 1990-07-04 1992-01-10 Cis Bio Int Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques.
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
EP0510132B1 (en) * 1990-09-28 1997-05-14 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
KR930703024A (ko) 1991-02-08 1993-11-29 리챠드 티. 딘 영상용 테크네튬-99m표지폴리펩티드
FR2679452B1 (fr) * 1991-07-22 1993-11-12 Cis Bio International Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
ATE196094T1 (de) 1992-05-21 2000-09-15 Diatide Inc Technetium-99m markierte peptide zur bilderzeugung von thrombus
GB2268494B (en) 1992-07-08 1996-08-21 Kenneth Francis Prendergast Imaging compositions
FR2698272B1 (fr) * 1992-11-20 1994-12-30 Cis Bio Int Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé.
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
LT4380B (lt) 1998-09-25
WO1996040637A1 (en) 1996-12-19
KR19990022573A (ko) 1999-03-25
IL118468A0 (en) 1996-09-12
SI9620076A (sl) 1998-08-31
BR9609003A (pt) 1999-12-14
US6015904A (en) 2000-01-18
ATE233241T1 (de) 2003-03-15
DE69626392D1 (de) 2003-04-03
NO975678D0 (no) 1997-12-05
EA199800025A1 (ru) 1998-06-25
AU6166196A (en) 1996-12-30
CZ380197A3 (cs) 1998-07-15
CA2222183A1 (en) 1996-12-19
LT97191A (en) 1998-04-27
SI9620076B (sl) 2000-02-29
HRP960250A2 (en) 1997-12-31
NO975678L (no) 1998-02-06
EA000742B1 (ru) 2000-02-28
EP0832068B1 (en) 2003-02-26
MY133974A (en) 2007-11-30
NZ310799A (en) 2000-01-28
EP0832068A1 (en) 1998-04-01
LV12044B (en) 1998-09-20
PL323995A1 (en) 1998-04-27
ZA964854B (en) 1997-12-08
US5750088A (en) 1998-05-12
ES2193245T3 (es) 2003-11-01
MX9709126A (es) 1998-03-31
AR003959A1 (es) 1998-09-30
CN1192733A (zh) 1998-09-09
HUP9901469A2 (hu) 1999-08-30
JPH11507364A (ja) 1999-06-29
AU718683B2 (en) 2000-04-20
EE9700313A (et) 1998-06-15
SK163497A3 (en) 1998-10-07
DE69626392T2 (de) 2004-04-22
LV12044A (lv) 1998-05-20

Similar Documents

Publication Publication Date Title
HUP9901469A3 (en) Stable reagents for the preparation of radiopharmaceuticals
PL325598A1 (en) Deriphenacin containing pharmaceutic preparation
IL117188A0 (en) Process for the preparation of thietanones
IL119496A0 (en) Process for the preparation of dihaloazolopyrimidines
GB9503240D0 (en) Preparation
PL321686A1 (en) Trensdermal preparation
IL116924A0 (en) Preparation of n-aryl- and n-hetarylhydroxylamines
AU5194798A (en) Process for the preparation of radiopharmaceuticals
IL133140A0 (en) Novel process for the preparation of 4-aryl-piperidines
ZA96841B (en) Structural member
ZA987741B (en) Process for the preparation of oxazaphosphorine-2-amines
IL115090A0 (en) Process for the preparation of p-bromofluorobenzene
HUP0001757A3 (en) Improved process for the preparation of halo-4-phenoxyquinolines
IL135553A0 (en) Process for the preparation of azacycloalkyalkanoyl pseudotetrapeptides
GB2300129B (en) Mixing
IL117786A (en) Preparation of alpha-bisoximes
GB9807032D0 (en) Process for the preparation of (S)-3-carbethoxy-3-benzylpiperidine
IL118732A (en) Process for the preparation of arylidene-substituted alkylcycloalkanones
IL118747A0 (en) Process for the preparation of 3-hydroxyoxetanes
IL132237A0 (en) Process for the preparation of 3-isochromanome
GB2307925B (en) Structural member
ZA981924B (en) Process for the preparation of n-carboxylalkyl-3-fluoro-4- dialkylaminoanilines
HU9500176V0 (en) Nounter of the tariff
IL148253A0 (en) Process for the preparation of 4-sulfanylpyrrolidin-2-yl
HU9500292V0 (en) Medicinal fastening for laboratory purpose